Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease
Abstract Introduction An Elecsys® Amyloid β (Aβ [1–42]) immunoassay cutoff for classification of patients with Alzheimer's disease was investigated. Methods Cerebrospinal fluid samples collected from patients with mild‐to‐moderate Alzheimer's disease were analyzed by Elecsys® immunoassays:...
Main Authors: | Leslie M. Shaw, Teresa Waligorska, Leona Fields, Magdalena Korecka, Michal Figurski, John Q. Trojanowski, Udo Eichenlaub, Simone Wahl, Marian Quan, Michael J. Pontecorvo, D. Richard Lachno, Jayne A. Talbot, Scott W. Andersen, Eric R. Siemers, Robert A. Dean |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
Subjects: | |
Online Access: | https://doi.org/10.1016/j.dadm.2018.07.002 |
Similar Items
-
Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
by: Eline A.J. Willemse, et al.
Published: (2018-01-01) -
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging
by: James D. Doecke, et al.
Published: (2020-03-01) -
Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort
by: Adelina Orellana, et al.
Published: (2022-06-01) -
P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
by: Michelle R. Campbell, et al.
Published: (2021-01-01) -
Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
by: Eline A. J. Willemse, et al.
Published: (2021-01-01)